GDC-4198

N/A

Report date: 2025/12/29 14:50:06
NME

Base Information

Drug NameGDC-4198
Drug Alias NameRGT-419BRGXXXXGDC-4198
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 4 inhibitorsCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 2 inhibitors
TargetsCyclin-dependent kinase 4Cyclin-dependent kinase 6Cyclin-dependent kinase 2
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesQILU Regor Therapeutics Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesQILU Regor Therapeutics IncF. Hoffmann-La Roche LtdRegor Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A